Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Thomas A. Penfound"'
Autor:
M. Taariq Salie, Babu Muhamed, Kélin Engel, Kimona Rampersadh, Rezeen Daniels, Lwazi Mhlanti, Thomas A. Penfound, Craig A. Sable, Liesl J. Zühlke, James B. Dale, Mark E. Engel
Publikováno v:
mSphere, Vol 8, Iss 3 (2023)
ABSTRACT There is limited information on the human immune response following infection with group A Streptococcus (Strep A). Animal studies have shown, in addition to the M protein, that shared Strep A antigens elicit protective immunity. This study
Externí odkaz:
https://doaj.org/article/1923fc3d235043ee9337f0cdea12782c
Publikováno v:
mSphere, Vol 3, Iss 6 (2018)
ABSTRACT The clinical development of group A streptococcal (GAS) vaccines will require the implementation of a standardized, high-throughput assay to measure the activity of functional opsonic antibodies in vaccine recipients. In the present study, w
Externí odkaz:
https://doaj.org/article/30a94378ff9a4a768bff82461ec567d5
Autor:
James B. Dale, Jeremy C. Smith, Thomas A. Penfound, Jay A. Spencer, Jerome Baudry, Michelle P. Aranha, Rupesh Agarwal
Publikováno v:
J Biol Chem
Group A streptococcus (Strep A) surface M protein, an α-helical coiled-coil dimer, is a vaccine target and a major determinant of streptococcal virulence. The sequence-variable N-terminal region of the M protein defines the M type and also contains
Autor:
Scott A. Halperin, Luis Martin, Joanne M. Langley, Shelly A. McNeil, Sanaz Salehi, Thomas A. Penfound, James B. Dale, Robert L Stewart, Lingyun Ye, Donna MacKinnon-Cameron, Elodie Pastural, Gregory J. Hurley
Publikováno v:
Vaccine. 38:1384-1392
Background Streptococcus pyogenes (group A Streptococcus, Strep A) is a widespread pathogen that continues to pose a significant threat to human health. The development of a Strep A vaccine remains an unmet global health need. One of the major vaccin
Autor:
Michelle P. Aranha, Thomas A. Penfound, Jeremy C. Smith, Anne Botteaux, Sanaz Salehi, Pierre Smeesters, James B. Dale
Publikováno v:
J Immunol
Group A streptococcal infections are a significant cause of global morbidity and mortality. A leading vaccine candidate is the surface M protein, a major virulence determinant and protective Ag. One obstacle to the development of M protein–based va
Autor:
James B. Dale, Claudia M. Hohn, Shannon E. Niedermeyer, Thomas A. Penfound, Adam Greeley, Harry S. Courtney
Publikováno v:
Clinical and Experimental Vaccine Research
Purpose There is a need to broaden protective coverage of M protein-based vaccines against group A streptococci (GAS) because coverage of the current 30-valent M protein vaccine does not extend to all emm types. An additional GAS antigen and virulenc
Autor:
James B. Dale, Thomas A. Penfound, Edward L. Kaplan, Nicholas D. Hysmith, Dwight R. Johnson, P. Patrick Cleary
Publikováno v:
J Pediatric Infect Dis Soc
Background. Despite the significant burden of disease associated with infection by group A streptococcus (GAS), little is known about the human immune response to GAS antigens after natural infection. Methods. We evaluated 195 serum samples obtained
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0585e9457f75772dd871bff3b521afa
https://europepmc.org/articles/PMC7207265/
https://europepmc.org/articles/PMC7207265/
Autor:
Joshua M. Svendsen, Thomas E. Bickett, Thomas A. Penfound, Victor C. Huber, Michael S. Chaussee, Margaret J. Schuneman, Joshua M. Klonoski, Brian A. Juber, Brandon Burum, James B. Dale, Grigoriy Sereda, Heather R. Hurtig
Publikováno v:
Vaccine. 32:5241-5249
Influenza virus infections are associated with a significant number of illnesses and deaths on an annual basis. Many of the deaths are due to complications from secondary bacterial invaders, including Streptococcus pneumoniae, Staphylococcus aureus,
Autor:
James P. Nataro, Samba O. Sow, Milagritos D. Tapia, Boubou Tamboura, Karen L. Kotloff, Thomas A. Penfound, James B. Dale
Publikováno v:
Vaccine. 31:1576-1581
Background The greatest burden of group A streptococcal (GAS) disease worldwide is due to acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Safe, effective and affordable vaccines designed to prevent GAS infections that trigger ARF could
Autor:
Claudia M. Hohn, Harry S. Courtney, Jerome Baudry, Pierre R. Smeesters, James B. Dale, Jeremy C. Smith, Thomas A. Penfound
Publikováno v:
Vaccine. 35(1)
Background A major obstacle to the development of broadly protective M protein-based group A streptococcal (GAS) vaccines is the variability within the N-terminal epitopes that evoke potent bactericidal antibodies. The concept of M type-specific prot